论文部分内容阅读
格列齐特缓释片是第一种创新的亲水基质剂型降糖药,其有效成分的释放与人体血糖波动相吻合,确保胰岛素适时适量地分泌,符合糖尿病血糖控制的需要,每天早餐时服用1次,提供24 h长效血糖控制。格列齐特缓释片具有卓越的安全性和良好的耐受性,极少发生低血糖,几乎不影响患者的体重。临床上,对于新诊断、二甲双胍控制不佳或短效促泌剂控制不佳的2型糖尿病患者,使用格列齐特缓释片治疗一段时间后均能取得显著疗效。
Gliclazide sustained-release tablets is the first innovative hydrophilic matrix dosage hypoglycemic agents, the release of its active ingredient in line with fluctuations in human blood glucose to ensure proper and timely secretion of insulin, in line with the needs of diabetic control of blood sugar, breakfast every day Take 1 time, provide long-term blood glucose control 24 h. Gliclazide has excellent safety and good tolerability, low hypoglycemia, almost no impact on the patient’s body weight. Clinically, patients with type 2 diabetes who are poorly diagnosed with metformin, poorly controlled metformin, or poorly controlled short-acting secretagogues can achieve significant results after treatment with gliclazide for extended periods of time.